Daré Bioscience, Inc. (DARE)
| Market Cap | 13.93M -22.6% |
| Revenue (ttm) | 1.37M +10,429.4% |
| Net Income | -10.99M |
| EPS | -0.78 |
| Shares Out | 14.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,087,945 |
| Open | 1.5500 |
| Previous Close | 1.3700 |
| Day's Range | 0.7650 - 1.6100 |
| 52-Week Range | 0.7650 - 3.7800 |
| Beta | 1.06 |
| Analysts | Strong Buy |
| Price Target | 9.67 (+939.79%) |
| Earnings Date | Aug 13, 2026 |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor sympto... [Read more]
Financial Performance
In 2025, Daré Bioscience's revenue was $1.03 million, an increase of 10429.36% compared to the previous year's $9,784. Losses were -$13.40 million, 230.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price target is $9.67, which is an increase of 939.79% from the latest price.
News
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Daré Bioscience Earnings Call Transcript: Q2 2026
Transitioned to commercial stage with first product launch and second nearing prescription dispensing. Q2 2026 saw improved net loss and increased SG&A for commercial readiness. Pipeline advances and non-dilutive funding support a diversified, scalable women's health portfolio.
Daré Bioscience Quarterly report: Q2 2026
Daré Bioscience has published its Q2 2026 quarterly earnings report on August 13, 2026.
Daré Bioscience Earnings release: Q2 2026
Daré Bioscience released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July
Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré's strategy to build a trusted women's health ecosystem spanning products, education and access ...
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Daré Bioscience Transcript: Virtual Investor Closing Bell
The event detailed a transition from development to commercialization, with two products—Flora Sync LF5 and DARE to PLAY—launching in 2024, supported by a robust pipeline and over $75 million in non-dilutive funding. Key clinical milestones for Ovaprene and DARE-HPV are expected in the next year, while the business model leverages digital platforms and provider networks for rapid adoption.
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Live video webcast on Tuesday, July 14 th , at 4:00 PM ET Register here
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers Commercial Launch Begins Company's First Consumer Revenue Strea...
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
First consumer health product positions Daré for revenue generation while expanding its women's health leadership platform
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health President and CEO, Sabrina Martucci Johnson, to par...
Daré Bioscience Transcript: AGM 2026
The meeting covered eight proposals, including director elections, auditor ratification, and amendments to the stock incentive plan. All proposals were approved, with no questions from stockholders.
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Dare Bioscience receives NIH funding award notice to advance DARE-HPV
Dare Bioscience (DARE) announced receipt of a Notice of Award from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, NIH, obligating the…
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 million Funding award milestone follows Daré's announcement last week of th...
Dare Bioscience initiates DARE-HPV clinical study
Dare Bioscience (DARE) announced the initiation of its Phase 2 clinical study of DARE-HPV, an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal inser...
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. governm...
Daré Bioscience Earnings Call Transcript: Q1 2026
Transitioning to a revenue-generating phase, first product revenue is expected in June 2026, with strong clinical and commercial momentum across a robust women's health pipeline. Cash runway is limited, but diversified capital sources and positive clinical milestones support growth.
Daré Bioscience Quarterly report: Q1 2026
Daré Bioscience has published its Q1 2026 quarterly earnings report on May 14, 2026.
Daré Bioscience Earnings release: Q1 2026
Daré Bioscience released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 202...
Dare Bioscience reports positive interim Phase 3 results for Ovaprene
Dare Bioscience (DARE) announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating Ovaprene, its investigational monthly, hormone-free intravaginal contra...